(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 16.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ardelyx's revenue in 2025 is $361,706,000.On average, 5 Wall Street analysts forecast ARDX's revenue for 2025 to be $86,126,612,705, with the lowest ARDX revenue forecast at $82,708,134,236, and the highest ARDX revenue forecast at $88,378,482,761. On average, 5 Wall Street analysts forecast ARDX's revenue for 2026 to be $109,036,256,275, with the lowest ARDX revenue forecast at $94,194,776,964, and the highest ARDX revenue forecast at $118,359,553,376.
In 2027, ARDX is forecast to generate $139,447,986,273 in revenue, with the lowest revenue forecast at $111,923,588,174 and the highest revenue forecast at $166,521,627,552.